Development of a High-Performance Immunoaffinity Separation Technique for Rare Cell Capture

Circulating tumor cell enrichment and enumeration are advancing early detection of cancer, monitoring of therapy response, and even next-generation therapies. Efficiently capturing rare cells from complex biological fluids is essential in both diagnostic and therapeutic applications. EpCAM-positive tumor cells are specifically captured by utilizing covalently immobilized anti-EpCAM monoclonal antibodies onto the surface of chemically modified glass microbeads. To maximize the capture efficiency, bead geometry, immobilization conditions, flow rate, and anticoagulant dosage were systematically optimized. An in vitro flow-capture system was designed and used to evaluate the capture efficiency of the proposed technology by utilizing HTC116 colon cancer cell-spiked model media. The effect of substrate surface pretreatment was characterized by goniometry, while the capture performance was monitored by flow cytometry and fluorescent microscopy. The specific capture ability of the bioactive microbead substrate reached over 130,000 cells in the laboratory-scale cartridge (V(cartridge) = 2.6 cm3; m(bead) = 4 g). This capture efficiency suggests a promising rare-cell capture utilization of the proposed technology and may be used for research, diagnostic, and therapeutic purposes. In this paper, we reported on the development and feasibility test of a high-performance bioactive glass-microbead cell capture substrate. Due to the relevance and novelty of the reported results, with further development, the versatile platform technology presented could be readily implemented to capture tumor cells from complex biological samples and represent an additional complementary tool to existing cancer diagnostics and therapies.